Therapeutic Targeting of Oxidative Phosphorylation in Microsatellite Instability-High Gastric Cancer
Journal of Cancer · 30.03.2026 · 17 (4) · 797-807
DOI: 10.7150/jca.127225 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cancer, erschienen am 30.03.2026. Verfasst von Bing Ang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
- Department of Hepatobiliary Surgery, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
- School of Medicine, Nankai University, Tianjin 300071, China.
- Tianjin First Central Hospital Clinic Institute, Tianjin Medical University, Tianjin 300192, China.
Zitieren
APA
Ang, B., Bai, Y., Deng, X., Wu, Q., Wang, Y., Xu, S., Zhang, W., Li, Y., Chen, D., Li, R., Li, S., Zhao, Z., & Zhang, Y. (2026). Therapeutic Targeting of Oxidative Phosphorylation in Microsatellite Instability-High Gastric Cancer. Journal of Cancer, 17(4), 797-807. https://doi.org/10.7150/jca.127225
Vancouver
Ang B, Bai Y, Deng X, Wu Q, Wang Y, Xu S, et al. Therapeutic Targeting of Oxidative Phosphorylation in Microsatellite Instability-High Gastric Cancer. Journal of Cancer. 2026;17(4):797-807. doi:10.7150/jca.127225
BibTeX
@article{Ang2026,
author = {Ang, Bing and Bai, Yi and Deng, Xiyue and Wu, Qiong and Wang, Yuqian and Xu, Shanshan and Zhang, Weixin and Li, Yang and Chen, Dapeng and Li, Ruixi and Li, Siyang and Zhao, Zhigang and Zhang, Yamin},
title = {Therapeutic Targeting of Oxidative Phosphorylation in Microsatellite Instability-High Gastric Cancer},
journal = {Journal of Cancer},
year = {2026},
volume = {17},
number = {4},
pages = {797--807},
doi = {10.7150/jca.127225}
}
EUVIMED